Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Clinical trial NCT05931042 · COMPLETED

Trial details

NCT number: NCT05931042
Sponsor: Rawalpindi Medical College
Status: COMPLETED
Study type: OBSERVATIONAL

HER2+ Breast Cancer

Start date: 2023-06-01
Primary completion: 2023-06-15
Enrollment: 1209

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.